Insects (whole body), mite dermatophagoides pteronyssinus - Biologic Drug Details

Summary for insects (whole body), mite dermatophagoides pteronyssinus

Tradenames:	1
High Confidence Patents:	0
Applicants:	5
BLAs:	5
Suppliers: see list	4

Pharmacology for insects (whole body), mite dermatophagoides pteronyssinus

Physiological Effect	Cell-mediated Immunity Increased Histamine Release Increased IgG Production
Established Pharmacologic Class	Standardized Insect Allergenic Extract
Chemical Structure	Allergens Antigens, Dermatophagoides Insect Proteins

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for insects (whole body), mite dermatophagoides pteronyssinus Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for insects (whole body), mite dermatophagoides pteronyssinus Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for insects (whole body), mite dermatophagoides pteronyssinus Derived from Patent Text Search

No patents found based on company disclosures

Insects (whole body), mite dermatophagoides pteronyssinus Market Analysis and Financial Projection

Last updated: February 15, 2026

What Are the Market Dynamics for Dermatophagoides Pteronyssinus-Based Insect-Based Biologic Drugs?

Growth in biologic drugs targeting dust mites, specifically Dermatophagoides pteronyssinus, is driven by increasing allergy prevalence and advances in immunotherapy. The global allergy immunotherapy market was valued at approximately $4.2 billion in 2021. It is projected to grow at a compound annual growth rate (CAGR) of about 8% through 2028, reaching nearly $7 billion. Demand stems from allergy diagnostics, symptomatic relief, and immunotherapy formulations.

Developers focus on allergen extracts, with some exploring isolates derived from whole body insects containing D. pteronyssinus proteins. Whole-insect biologics are in early research phases, with no established commercial products yet.

Major market segments include:

• Allergen-specific immunotherapy (ASIT): administered via injections or sublingually.
• Diagnostic tests: skin prick and serum IgE assessments.
• Adjunct therapeutics: combination with steroids or antihistamines.

Market players encompass pharmaceutical giants like ALK-Abelló, HAL (Hal Allergy), and Stallergenes Greer. There is increased investment from biotech startups exploring insect-based allergen sources, especially in Asia-Pacific, due to high allergy prevalence.

Regulatory environment impacts market expansion. The U.S. FDA regulates allergen extracts as biologics under the Public Health Service Act, requiring extensive safety and efficacy data. EU nations have similar regulations via the European Medicines Agency. Approval pathways favor well-characterized allergen extracts and recombinant forms, not whole insects or insect-derived biologics, complicating market entry for insect-based products.

How Is the Financial Trajectory of D. pteronyssinus Insect-Based Biologics Evolving?

Commercial development of whole-body insect biologics featuring D. pteronyssinus proteins remains in preclinical or clinical trial stages. No licensed biologics solely based on whole insects are currently marketed. However, the potential for therapeutic commercialization exists, especially as recombinant allergen manufacturing matures.

Key factors influencing financial projections include:

• R&D Investments: Companies are investing heavily in isolating and characterizing D. pteronyssinus antigens. Expected expenditures range from $50 million to over $200 million over the next five years before regulatory approval.
• Market Penetration: Commercial success depends on product safety, efficacy, and patient acceptance. The existing allergen immunotherapy market demonstrates an average annual revenue per product of $150 million, with top players holding substantial market shares.
• Pricing: Allergy biologics are priced between $300 and $600 per treatment cycle. Whole insect-derived biologics could command similar or higher prices due to novel sourcing and potential efficacy advantages.
• Regulatory Costs & Timeline: Approval could take 7–10 years, with regulatory submission costs exceeding $10 million for initial filings. Parallel development of recombinant allergen therapies may shorten time to market.

While total market opportunity for insect-based D. pteronyssinus biologics is uncertain, projects could generate revenue streams in the range of $500 million to $2 billion annually once commercially scaled, assuming successful regulation and consumer adoption.

What Are the Challenges and Opportunities in Commercializing Whole-Body Insect Biologics?

Challenges:

• Regulatory approval hurdles due to lack of precedent for whole insects as biologics.
• Manufacturing complexity: ensuring consistency, safety, and efficacy of insect-derived products.
• Patient acceptance: cultural and allergenic concerns surrounding insect-based products.
• Intellectual property issues: patenting insect-based allergen sources may be complicated.

Opportunities:

• Novel allergen sources with potentially enhanced immunogenicity.
• Addressing allergen variability by engineering recombinant or purified allergen formulations.
• Entering emerging markets with high allergy prevalence.
• Expanding indications beyond allergy, such as broader immunomodulatory applications.

What Are Key Market and Financial Indicators?

Indicator	Data / Projection
Global allergy immunotherapy market (2021)	$4.2 billion
CAGR (2022–2028)	8%
Projected market size (2028)	Nearly $7 billion
R&D investment per project	$50M–$200M over five years
Average annual revenue per product	$150M
Regulatory approval timeline	7–10 years
Regulatory approval costs	>$10M
Potential annual revenue (post-launch)	$500M–$2B

Key Takeaways

• The allergy immunotherapy market is expanding, with increasing demand for novel allergen sources.
• Whole insect biologics, specifically those derived from D. pteronyssinus, are currently in early development, with significant R&D investment needed before commercialization.
• Regulatory and manufacturing challenges limit immediate market entry but present opportunities for highly differentiated products.
• The financial trajectory hinges on successful regulatory approval, patient acceptance, and market penetration.
• Asia-Pacific represents an emerging focus for insect-based allergens, driven by high allergy prevalence and limited existing therapies.

FAQs

1. Are there already marketed insect-based allergen biologics targeting D. pteronyssinus?
No, current products are allergen extracts derived from D. pteronyssinus, not insect-based biologics involving whole insects. Whole insect biologics are under research.

2. What regulatory pathways exist for insect-based biologics?
They fall under biologics regulations, requiring FDA or EMA approval based on safety and efficacy data. There are no specific pathways for whole insects, complicating approval efforts.

3. How does the manufacturing of whole-body insect biologics compare to recombinant allergen production?
Whole insect manufacturing involves biological cultivation and extraction, which introduces variability and complexity. Recombinant production offers more consistency, easier scaling, and potentially lower costs.

4. What patient populations are likely to benefit most from insect-based biologics?
Patients with dust mite allergies, particularly those unresponsive or allergic to existing therapies, could benefit. Pediatric and severely allergic individuals are primary targets.

5. What are the potential advantages of insect-based biologics over existing allergy treatments?
They may provide higher immunogenicity, longer-lasting effects, or better coverage of allergen variability, leading to improved efficacy.

References

1. MarketsandMarkets. "Allergy Immunotherapy Market by Product, Route of Administration, End User – Global Forecast to 2028." 2022.
2. U.S. FDA. "Guidance for Industry: Allergenic Extracts." 2020.
3. European Medicines Agency. "Guidelines on allergen products for sensitization and allergy testing." 2021.
4. Grand View Research. "Allergy Immunotherapy Market Size, Share & Trends." 2022.
5. ChemIsThere. "Insect-based allergens for immunotherapy: Current landscape." 2023.